BIVACOR INC

From the company

BiVACOR is a clinical-stage medical device company pioneering the development of a long-term therapy for patients with biventricular heart failure. It develops a Total Artificial Heart (TAH), an electro-mechanical rotary blood pump with a single magnetically levitated rotor that pumps blood to both the body and lungs. The TAH is undergoing an FDA-approved first-in-human Early Feasibility Study, with first implantation completed July 9, 2024. Headquartered in Huntington Beach, California, with clinical offices in Houston, Texas, and international offices